Lab on chips

Lab on Chips Market Outlook

The global lab-on-chips market is projected to reach USD 10.55 billion by 2035, growing at a CAGR of 19.43% from 2025 to 2035. The rapid advancement in microfluidic technology, coupled with the increasing demand for point-of-care diagnostics, is primarily driving market growth. Furthermore, the rising prevalence of chronic diseases and the need for efficient and rapid testing methods in healthcare settings are significant contributing factors. Innovations in biotechnology and significant investments in research and development are enhancing the capabilities of lab-on-chip devices, which is further propelling market expansion. Additionally, the trend towards personalized medicine is expected to create new opportunities for lab-on-chip applications across various medical fields.

Growth Factor of the Market

One of the key growth factors for the lab-on-chip market is the increasing demand for miniaturized devices that offer lab-level analyses at reduced costs and faster turnaround times. This miniaturization directly correlates with the rise in point-of-care testing (POCT), which allows healthcare professionals to diagnose and treat patients more efficiently, particularly in remote or underserved areas. Furthermore, the integration of advanced technologies such as artificial intelligence and machine learning into lab-on-chip systems is enhancing their accuracy and functionality, making them more attractive to end-users. The growing focus on personalized medicine is also contributing to the market, as lab-on-chip devices can be tailored for specific patient needs, leading to better outcomes. In addition, regulatory support and favorable government policies aimed at promoting innovative diagnostic methods are expected to stimulate market growth. Lastly, the increasing investment in research and development by various stakeholders in the healthcare and biotechnology sectors reinforces the market's potential for expansion.

Key Highlights of the Market

• The global lab-on-chip market is expected to witness significant growth, reaching USD 10.55 billion by 2035.
• Technological advancements and miniaturization of diagnostic devices are key drivers of market expansion.
• Point-of-care testing is increasingly favored for its efficiency and convenience in various healthcare settings.
• Personalized medicine and tailored diagnostics present new opportunities for lab-on-chip applications.
• Government initiatives and funding for biotechnology research further bolster market potential.

By Product Type

DNA Microarrays:

DNA microarrays are among the leading product types in the lab-on-chip market, utilized primarily for genomic analysis. These devices allow for the simultaneous analysis of thousands of DNA sequences, which is instrumental in gene expression profiling, genotyping, and mutation detection. Their ability to deliver high-throughput results has made them invaluable in research facilities and clinical laboratories. The growing focus on personalized medicine necessitates comprehensive genetic profiling, thus driving the demand for DNA microarrays. Moreover, advancements in microarray technology, such as enhanced sensitivity and specificity, are further anticipated to propel their adoption in diagnostics and drug discovery processes.

Protein Microarrays:

Protein microarrays serve as another prominent segment in the lab-on-chip market, facilitating the analysis of protein interactions and functions simultaneously. These devices have become essential tools in proteomics, enabling researchers to study protein expressions, interactions, and their roles in various biological processes. The continuous advancements in antibody production and detection techniques are enhancing the capabilities of protein microarrays, thereby expanding their applications in biomarker discovery and therapeutic development. As the understanding of diseases at the proteomic level evolves, the demand for protein microarrays is expected to witness substantial growth, particularly in pharmaceutical and research settings.

Cell-based Assays:

Cell-based assays are critical components of the lab-on-chip market, allowing for real-time monitoring of cellular responses to various stimuli. These assays provide valuable insights into cell behavior and are extensively used in drug discovery, toxicology testing, and disease modeling. The integration of microfluidic technologies with cell-based assays enhances their efficiency and accuracy, leading to increased adoption in both academic and industrial laboratories. Moreover, the growing focus on high-throughput screening and the need for more physiologically relevant models are further driving the demand for advanced cell-based assays in pharmaceutical research.

Organ-on-Chips:

Organ-on-chips technology represents a revolutionary advancement in the lab-on-chip market by simulating human organ functions on a microfluidic platform. These devices allow for the study of complex biological systems and drug interactions in a more realistic environment compared to traditional cell cultures. The ability to replicate the physiological conditions of human organs is crucial for accurately assessing drug efficacy and toxicity. As the pharmaceutical industry increasingly seeks alternatives to animal testing, the demand for organ-on-chips is expected to surge. Ongoing research and development efforts to incorporate multiple organ systems into single devices will further enhance their applicability and market growth.

Others:

This category encompasses various other lab-on-chip products that do not fall neatly into the aforementioned classifications. These may include biosensors, lab-on-chip systems for environmental monitoring, and customized microfluidic devices developed for specific applications. The versatility of lab-on-chip technologies allows for innovations across multiple sectors, including food safety testing and industrial process monitoring. As new applications emerge and technology evolves, the 'Others' segment is anticipated to experience growth commensurate with advancements in microfluidic systems and their expanding role in diverse fields.

By Application

Drug Discovery:

Drug discovery is a significant application area for lab-on-chip technologies, enabling researchers to streamline the drug development process. These devices facilitate high-throughput screening and allow for the rapid assessment of drug candidates' efficacy and safety. By mimicking human biology more accurately than traditional methods, lab-on-chip systems improve the predictive power of preclinical studies and reduce the time and cost associated with drug development. The rising prevalence of various diseases and the need for innovative therapeutic solutions are driving the adoption of lab-on-chip technologies in drug discovery, ultimately leading to a more efficient pipeline for new medications.

Genomics:

Genomics is another key application area for lab-on-chip devices, as these technologies enable comprehensive analysis of genetic material. With growing interest in personalized medicine and targeted therapies, the demand for genomic analysis tools is surging. Lab-on-chip devices facilitate rapid sequencing and genotyping, significantly reducing the time required for genetic testing. The increasing prevalence of genetic disorders and the need for effective screening methods are driving the adoption of lab-on-chip solutions in genomics. Furthermore, advancements in sequencing technologies are expected to spur innovation and the development of more sophisticated lab-on-chip systems tailored for genomic applications.

Proteomics:

Proteomics, the large-scale study of proteins and their functions, is significantly benefiting from advancements in lab-on-chip technologies. These devices enhance the analysis of protein expression, interactions, and modifications, allowing researchers to better understand biological processes and disease mechanisms. The increasing focus on biomarker discovery and personalized medicine is further propelling the demand for lab-on-chip technologies in proteomics. With the ability to conduct high-throughput analyses and integrate multiple assays on a single chip, lab-on-chip systems are becoming indispensable tools in proteomic research and clinical diagnostics.

Disease Diagnosis:

Lab-on-chip technologies play a crucial role in disease diagnosis, enabling rapid and accurate testing in various medical conditions. The rise of point-of-care testing has heightened the demand for these devices, as healthcare providers seek to deliver timely diagnoses to improve patient outcomes. Lab-on-chip systems are utilized for a wide range of diagnostic applications, including infectious disease detection, cancer biomarker identification, and metabolic disorder screening. The growing emphasis on early diagnosis and preventive healthcare is expected to drive the adoption of lab-on-chip technologies in clinical settings, contributing to overall market growth in this application area.

Others:

The 'Others' category in the application segment includes various niche applications of lab-on-chip technologies, such as environmental monitoring, food safety testing, and quality control in industrial processes. These applications leverage the unique capabilities of lab-on-chip devices to deliver rapid and reliable analysis across diverse fields. As awareness of the importance of safety and compliance grows in various industries, the demand for lab-on-chip solutions in these areas is expected to increase. The expanding range of applications demonstrates the versatility of lab-on-chip technologies and their potential for future market growth.

By End User

Hospitals:

Hospitals represent a critical end-user segment for lab-on-chip technologies, as these devices facilitate rapid diagnostics and patient monitoring directly at the point of care. The adoption of lab-on-chip devices in hospital settings is driven by the need for timely diagnosis and treatment, particularly for infectious diseases and chronic conditions. Enhanced operational efficiency and reduced turnaround times for test results contribute to improved patient outcomes and resource management in hospitals. Moreover, the trend towards personalized medicine is influencing hospitals to integrate lab-on-chip solutions into their diagnostic capabilities, further boosting demand in this sector.

Diagnostic Centers:

Diagnostic centers are increasingly incorporating lab-on-chip technologies to enhance their testing capabilities and deliver accurate results more efficiently. These centers rely on rapid diagnostic tools to perform a wide range of tests, including genetic, proteomic, and metabolic analyses. The high throughput and cost-effectiveness of lab-on-chip devices make them attractive options for diagnostic centers striving to meet the growing demand for testing services. Furthermore, as awareness of the importance of early disease detection rises, diagnostic centers are motivated to adopt innovative technologies that can provide reliable results promptly, thus driving market growth.

Research Institutes:

Research institutes are pivotal end users of lab-on-chip technologies, utilizing these devices for a variety of applications ranging from fundamental research to applied sciences. The ability to conduct complex analyses in a miniaturized format allows research institutes to explore new avenues in biotechnology, genomics, and proteomics. Lab-on-chip devices enable researchers to gather data more efficiently and with higher precision, fostering advancements in scientific discovery. As funding for research continues to grow and collaborative projects expand, the demand for lab-on-chip technologies in research institutes is expected to rise significantly in the coming years.

Pharmaceutical Companies:

Pharmaceutical companies are increasingly leveraging lab-on-chip technologies in drug discovery and development processes. These devices expedite the identification of drug candidates by providing high-throughput screening capabilities and enabling more accurate assessments of drug efficacy and safety. The integration of lab-on-chip solutions into pharmaceutical research pipelines enhances the efficiency of the drug development process, ultimately leading to faster time-to-market for new therapies. The growing focus on personalized medicine and precision health is also driving pharmaceutical companies to adopt lab-on-chip technologies that allow for tailored therapeutic approaches, bolstering market growth within this segment.

Others:

The 'Others' category encompasses various end users of lab-on-chip technologies, including academic institutions, biotechnology firms, and environmental monitoring agencies. As the applications of lab-on-chip devices continue to expand, a diverse range of end users is adopting these technologies to enhance their analytical capabilities. The flexibility of lab-on-chip systems enables customization for specific applications, making them suitable for various industries beyond healthcare. As awareness of the benefits of lab-on-chip technologies grows, an increasing number of end users are expected to integrate these devices into their operations, further driving market growth.

By Material Type

Silicon:

Silicon is a widely used material in the fabrication of lab-on-chip devices, primarily due to its favorable electrical properties and compatibility with microfabrication techniques. Silicon-based lab-on-chip systems allow for precise control over fluid dynamics and enhanced functionality, making them suitable for a variety of applications, including biosensing and chemical analysis. The continued advancements in silicon microfabrication technologies are expected to support the growth of this segment, as researchers seek to develop more sophisticated lab-on-chip devices with improved performance and sensitivity. As the demand for high-quality diagnostics and research tools increases, the reliance on silicon-based materials is anticipated to persist.

Glass:

Glass is another prominent material utilized in lab-on-chip technology, particularly in applications requiring high optical transparency and chemical inertness. Glass-based lab-on-chip devices enable accurate optical measurements and are often employed in biosensing applications where sample integrity is crucial. The durability and biocompatibility of glass materials contribute to the growth of this segment, as researchers seek reliable and stable platforms for their analyses. Furthermore, innovations in glass microfabrication techniques and the development of hybrid materials that combine glass with other substances are expected to drive advancements in lab-on-chip technology, enhancing their applicability across various fields.

Polymer:

Polymer materials have gained significant traction in the lab-on-chip market due to their versatility, cost-effectiveness, and ease of fabrication. Polymer-based lab-on-chip devices can be produced using soft lithography techniques, facilitating rapid prototyping and customization for specific applications. The flexibility of polymers allows for the integration of various functionalities, including fluidic channels, sensors, and actuation mechanisms, making them suitable for a wide range of uses. As the demand for portable and inexpensive diagnostic tools continues to rise, polymer materials are expected to play a vital role in the expansion of the lab-on-chip market, particularly in point-of-care applications.

Others:

The 'Others' category includes various materials utilized in the production of lab-on-chip devices, such as metals and composite materials. These materials may be employed to enhance specific properties of lab-on-chip systems, such as conductivity or mechanical strength. Innovations in material science are leading to the development of hybrid lab-on-chip devices that combine different materials to optimize performance. As researchers explore new avenues for enhancing lab-on-chip technology, the use of alternative materials is anticipated to grow, further diversifying the market and expanding its applications.

By Region

The North American lab-on-chip market is anticipated to hold the largest share during the forecast period, attributed to the presence of advanced healthcare infrastructure, significant investments in research and development, and a strong focus on innovation. The U.S. dominates the market, driven by leading pharmaceutical companies and research institutions that are early adopters of lab-on-chip technologies. As the region continues to witness an increase in chronic disease prevalence and demand for rapid diagnostics, the lab-on-chip market in North America is expected to grow at a CAGR of 20.12%, reflecting a robust trend towards integrating advanced diagnostics in clinical settings.

Europe follows closely behind North America, with a growing market for lab-on-chip technologies in countries such as Germany, the UK, and France. The European market benefits from supportive regulations and funding for biotechnology research, fostering innovation and development in lab-on-chip applications. Additionally, the increasing focus on personalized medicine and preventive healthcare is driving the demand for rapid diagnostic tools within the region. As the market matures, collaborations between academic institutions and industry players are expected to enhance the growth of lab-on-chip technologies in Europe, making it a significant player in the global landscape.

Opportunities

The lab-on-chip market is poised for substantial growth in the coming years, driven by several emerging opportunities. One significant opportunity lies in the increasing demand for point-of-care testing (POCT) solutions. As healthcare providers seek to deliver immediate and accurate diagnostics, lab-on-chip technologies can facilitate rapid testing at the site of patient care. This trend is especially pertinent in remote areas where access to centralized laboratory facilities may be limited. The integration of lab-on-chip devices into portable diagnostic systems enhances accessibility and convenience, catering to the need for efficient healthcare solutions globally. Furthermore, advancements in microfluidics and integration with digital technologies present opportunities for developing more sophisticated lab-on-chip systems that can perform complex analyses while being user-friendly.

Another promising opportunity exists in the field of personalized medicine, where lab-on-chip technologies can be tailored to accommodate specific patient profiles. The growing emphasis on individualized treatment plans necessitates tools that can rapidly analyze genetic, proteomic, and metabolic factors. Lab-on-chip devices hold the potential to provide real-time data that can inform personalized therapeutic approaches, thus improving patient outcomes. This shift towards personalized healthcare is expected to drive innovation in lab-on-chip technologies, enabling researchers and healthcare providers to develop customized solutions that align with the unique needs of patients. As the healthcare landscape evolves, the ongoing demand for personalized diagnostics will likely present lucrative opportunities for growth within the lab-on-chip market.

Threats

Despite the promising growth prospects, the lab-on-chip market faces several threats that could impede its expansion. One significant threat is the stringent regulatory environment associated with medical devices and diagnostic tools. Regulatory bodies impose rigorous standards for safety, efficacy, and performance, which can pose challenges for manufacturers seeking to bring new lab-on-chip products to market. The lengthy approval processes can delay product launches and increase costs for companies, hindering their ability to innovate and adapt to market demands. Additionally, variations in regulatory requirements across different regions can complicate the global distribution of lab-on-chip technologies, further challenging companies operating on an international scale.

Another potential threat to the lab-on-chip market is the rapid pace of technological advancement, which can lead to increased competition and market saturation. As more companies enter the lab-on-chip space and invest in microfluidic technologies, the competition for market share intensifies. Established players may face challenges from emerging startups that introduce disruptive technologies or innovative applications. Furthermore, the continuous evolution of diagnostic methods, such as the rise of next-generation sequencing and other advanced testing platforms, could render some lab-on-chip devices obsolete. To remain competitive, companies must prioritize research and development, continually enhance their product offerings, and stay attuned to evolving market trends to mitigate the risk of obsolescence.

Competitor Outlook

• Thermo Fisher Scientific
• Agilent Technologies
• Abbott Laboratories
• Roche Diagnostics
• Fluidigm Corporation
• Bio-Rad Laboratories
• Siemens Healthineers
• PerkinElmer, Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche AG
• Qiagen N.V.
• Schrödinger, Inc.
• Micronit Microfluidics
• Elveflow
• Wyatt Technology Corporation

The competitive landscape of the lab-on-chip market is characterized by a mix of established players and innovative startups, both striving to capture market share through technological advancements and strategic partnerships. Key companies are focusing on research and development to introduce cutting-edge lab-on-chip devices that cater to various applications in healthcare, biotechnology, and environmental monitoring. Furthermore, collaborations with academic institutions and research organizations are becoming increasingly common, as companies seek to leverage external expertise and resources to accelerate product development and enhance their competitive positioning. The emphasis on point-of-care testing and personalized medicine is driving companies to develop portable and user-friendly lab-on-chip systems that meet the evolving demands of healthcare professionals and patients alike.

Major companies such as Thermo Fisher Scientific and Abbott Laboratories are leading the charge in the lab-on-chip market, leveraging their extensive portfolios and established reputations to introduce innovative products. Thermo Fisher, for instance, offers a range of lab-on-chip solutions for genetic analysis and protein characterization, positioning itself as a key player in the diagnostics landscape. Abbott Laboratories, known for its strong presence in point-of-care testing, is actively investing in lab-on-chip technologies that enhance diagnostic capabilities and improve patient outcomes. Both companies are also focusing on strategic acquisitions and collaborations to strengthen their market positions and expand their product offerings.

In addition to established players, several startups and emerging companies are shaking up the lab-on-chip market with novel technologies and applications. For example, Fluidigm Corporation specializes in microfluidic systems that enable high-throughput genomic analysis and single-cell studies. Their innovative lab-on-chip devices are driving advancements in personalized medicine and drug discovery. Similarly, companies like Qiagen and Bio-Rad Laboratories are investing in lab-on-chip technologies tailored for molecular diagnostics and proteomics, catering to the growing demand for rapid and accurate testing solutions. As the market continues to evolve, the dynamic interplay between established corporations and newcomers will shape the future trajectory of the lab-on-chip landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Elveflow
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Illumina, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 PerkinElmer, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Diagnostics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Abbott Laboratories
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Agilent Technologies
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Bio-Rad Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Fluidigm Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Micronit Microfluidics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 F. Hoffmann-La Roche AG
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Schrödinger, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Wyatt Technology Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Lab on chips Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Research Institutes
    • 6.1.4 Pharmaceutical Companies
    • 6.1.5 Others
  • 6.2 Lab on chips Market, By Application
    • 6.2.1 Drug Discovery
    • 6.2.2 Genomics
    • 6.2.3 Proteomics
    • 6.2.4 Disease Diagnosis
    • 6.2.5 Others
  • 6.3 Lab on chips Market, By Material Type
    • 6.3.1 Silicon
    • 6.3.2 Glass
    • 6.3.3 Polymer
    • 6.3.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Lab on chips Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Lab on chips market is categorized based on

By Application

• Drug Discovery
• Genomics
• Proteomics
• Disease Diagnosis
• Others

By End User

• Hospitals
• Diagnostic Centers
• Research Institutes
• Pharmaceutical Companies
• Others

By Material Type

• Silicon
• Glass
• Polymer
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific
• Agilent Technologies
• Abbott Laboratories
• Roche Diagnostics
• Fluidigm Corporation
• Bio-Rad Laboratories
• Siemens Healthineers
• PerkinElmer, Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche AG
• Qiagen N.V.
• Schrödinger, Inc.
• Micronit Microfluidics
• Elveflow
• Wyatt Technology Corporation